Sacituzumab a 'Step Forward' in Breast Cancer Unmet Need
Sacituzumab govitecan (Trodelvy) beat chemotherapy in patients with heavily pretreated endocrine resistant HR+/HER2- advanced breast cancer, who represent a 'great clinical unmet need,' says expert.
Medscape Medical News
source https://www.medscape.com/viewarticle/975069?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/975069?src=rss
Comments
Post a Comment